These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37497303)

  • 1. Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT.
    Giza A; Miklusiak K; Hałubiec P; Jaworek A; Zimowska-Curyło D; Dyduch G; Sacha T
    Case Rep Dermatol; 2023; 15(1):110-116. PubMed ID: 37497303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
    O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
    J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large-cell transformation: A novel histologic finding.
    Buchely N; Al-Rohil RN; Aung PP; Jour G; Torres-Cabala C; Prieto VG; Ivan D
    J Cutan Pathol; 2018 May; ():. PubMed ID: 29806104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
    Raghavan SS; Hong EK; Kim YH; Kim J
    J Cutan Pathol; 2019 Jan; 46(1):33-43. PubMed ID: 30328119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral mycosis fungoides with CD30
    Goggins CA; Gocke MT; Jang S; DeSimone JA
    JAAD Case Rep; 2019 Feb; 5(2):180-183. PubMed ID: 30733988
    [No Abstract]   [Full Text] [Related]  

  • 7. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
    Muniesa C; Gallardo F; García-Doval I; Estrach MT; Combalia A; Morillo-Andújar M; De la Cruz-Vicente F; Machan S; Moya-Martínez C; Rovira R; Sanchez-Gonzalez B; Acebo E; Amutio E; Peñate Y; Losada-Castillo MDC; García-Muret MP; Iznardo H; Román-Curto C; Cañueto J; Fernández-de-Misa R; Flórez Á; Izu RM; Torres-Navarro I; Zayas A; Pérez-Paredes G; Blanes M; Yanguas JI; Pérez-Ferriols A; Callejas-Charavia M; Ortiz-Romero PL; Pérez-Gil A; Prieto-Torres L; González-Barca E; Servitje O
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):57-64. PubMed ID: 36017748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of mycosis fungoide : focus on brentuximab vedotin].
    Lebas E; Collins P; Bonnet C; Libon F; Dezfoulian B; Nikkels AF
    Rev Med Liege; 2021 Apr; 76(4):224-231. PubMed ID: 33830684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatially Resolved Transcriptomes of CD30+-Transformed Mycosis Fungoides and Cutaneous Anaplastic Large-Cell Lymphoma.
    Choi ME; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
    J Invest Dermatol; 2024 Feb; 144(2):331-340.e2. PubMed ID: 37544586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
    Goyal A; Hordinsky M; Lazaryan A
    Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
    Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
    Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dramatic response to brentuximab vedotin in refractory nontransformed CD30
    Mahévas T; Ram-Wolff C; Battistella M; Pennamen MDV; Rivet J; Brice P; Bagot M
    Br J Dermatol; 2019 Jun; 180(6):1517-1520. PubMed ID: 30269331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
    Kim SJ; Do YR; Lee HS; Lee WS; Kong JH; Kwak JY; Eom HS; Moon JH; Yi JH; Lee JO; Jo JC; Yang DH
    Blood Res; 2023 Dec; 58(4):194-200. PubMed ID: 38031473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.
    Giordano A; Pagano L
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022029. PubMed ID: 35444765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
    Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
    Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.